Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review.
This paper aims to systematically review the influence of apolipoprotein E (ApoE) on the effects of potentially modifiable mid and late life risk factors for dementia. Scopus, Medline, PubMed, PsycINFO, and HuGE databases were searched up to November 2008. Two independent reviewers selected 94 articles from 13,122 results. Results suggest the deleterious effect of current smoking is limited only to persons without ApoE epsilon 4 (4 out of 4 studies), ApoE epsilon 4 increases the risk of dementia associated with greater fat consumption, particularly saturated fats (3 out of 4 studies), and increases the protective effect against dementia associated with HRT use (3 out of 5 with one of the non-significant studies suggesting a trend). There was evidence that ApoE does not modify the risk of dementia associated with measures of, and treatments for CVD, other dietary factors, and estradiol levels. There was inconsistent or contradictory evidence for other environmental factors reviewed. There is insufficient evidence for the recommendation of ApoE testing to assist with tailoring risk reduction recommendations for dementia.
Low
Lee-Fay
LF
Dementia Collaborative Research Centre: Assessment and Better Care Outcomes, University of New South Wales, Kensington 2500, New South Wales, Australia. lf.low@unsw.edu.au
Yap
Melvyn H W
MH
Brodaty
Henry
H
D001057:Apolipoproteins E / Q000235:genetics*; D003704:Dementia / Q000175:diagnosis / Q000235:genetics* / Q000517:prevention & control*; D020022:Genetic Predisposition to Disease; D006801:Humans; D012307:Risk Factors; D040242:Risk Reduction Behavior
D001057:Apolipoproteins E